Wall Street Zen Downgrades Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) to Sell

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of Lakewood-Amedex Biotherapeutics stock opened at $0.68 on Friday. Lakewood-Amedex Biotherapeutics has a 12 month low of $0.66 and a 12 month high of $9.82.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.